Date: November 21, 2026
Regulatory Compliance Update
Aurobindo Pharma Limited disclosed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the United States Food and Drug Administration (USFDA) inspection of Unit-VI, an API manufacturing facility of its wholly owned subsidiary Apitoria Pharma Private Limited, has been closed.
Inspection Details
- Facility: Unit-VI, API manufacturing facility of Apitoria Pharma Private Limited
- Location: E-Bonangi Village, Parawada Mandal, Anakapalli District, 531019, Andhra Pradesh
- Inspection Period: August 24 to August 28, 2026
- Observations: Concluded with three observations
Inspection Outcome
- Classification: Voluntary Action Indicated (VAI)
- Status: Inspection is now closed
- Documentation: Establishment Inspection Report (EIR) received
Reference
This disclosure references the company's previous letter dated August 28, 2026.